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tive was to determine the impact of the PDL on net costs and
utilization of LANA, total narcotic analgesics, and non-narcotic
substitute drugs. METHODS: We obtained Arkansas Medicaid
claims data from January 2003 to July 2007. Net costs based on
CMS-rebates and mg of morphine equivalents (MEq) obtained
from standardized conversion tables were the primary outcome
variables. Autoregressive-integrated-moving-average ARIMA
time series models of monthly measures were estimated. Inter-
rupted OLS time series models were estimated to capture the
impact of the policy on the shifts in trend and intercept.
RESULTS: There were 709,791 Medicaid eligibles, of which
3,227 used a LANA whom had an average age of 44.65 years,
39.36% male, and 80.54% white. The PDL was associated with
a $1.41 million (95%CI: $0.37–$2.43 million) and a $1.78
million (95%CI: $0.48–$3.05 million) cost reduction for LANA
and total narcotic analgesics over the 22-month post-policy
period. Total narcotic utilization was not signiﬁcantly different
than trend utilization for 18 months of the post-policy period.
The PDL was associated with a signiﬁcant increase in C-II short-
acting narcotic utilization of 202,828 (95%CI: 68,160–337,497)
MEq and non-signiﬁcant decreases in C-II LANA and CIII-V
narcotic utilization. A sensitivity analysis with a term to capture
the effect of generic fentanyl availability yielded more conserva-
tive cost saving estimates. There was no PDL-related increase
in the utilization of benzodiazepines, migraine agents, NSAIDs,
muscle-relaxants, anticonvulsants, or antidepressants. CON-
CLUSIONS: The PDL resulted in signiﬁcant cost savings for
narcotic analgesics. The policy did not consistently affect the
overall level of narcotic analgesia prescribed, however, the policy
may have steered patients toward shorter acting narcotics.
PSY63
PATIENT-REPORTED OUTCOMES (PRO’S) AND ECONOMICS
OF NEUROPATHIC PAIN IN GERMANY
Breitscheidel L1, Kreyenberg K1, Stridde E2, Eichmann F1
1Kendle GmbH, Munich, Germany, 2Pﬁzer Pharma GmbH, Karlsruhe,
Germany
OBJECTIVES: To evaluate health care resource use, costs and
patient-reported outcomes (PRO’s) among patients with neuro-
pathic pain, speciﬁcally for guideline-, non-guideline- and self-
treatment-groups in Germany. METHODS: Patients were
consecutively recruited by physicians in general practice (n = 47)
in 2005. Data on resource utilization due to neuropathic pain
was collected retrospectively for six months. Costs were esti-
mated from the societal perspective. PRO were assessed through
generic SF-36 and disease-speciﬁc von Korff Index, and Patient
Health Questionnaire Depression (PHQ-D) questionnaires at
time of recruitment. Groups were compared using multivariable
general linear modeling (GLM). RESULTS: Ninety-nine patients
took part in this study (n = 44 self-treatment, n = 23 guideline,
n = 32 non-guideline-groups). The majority of patients were
overweight, 61% of all patients were women, and 29% were
currently employed. Average duration of neuropathic pain was
about 6.2 years and was comparable among the groups. Patients
in the self-treatment-group were younger than patients in guide-
line or non-guideline-group (mean age 54.5 vs. 67.6 vs. 66.9
years, p < 0.0001). Mean total costs per patient and 6 months
were €674.23 [95%CI 225.95; 1122.51] vs. €1507.21 [95%CI
715.48; 2298.94] vs. €1426.24[95%CI 850.18; 2002.30] (self-
treatment-vs. guideline vs. non-guideline-group, respectively,
p = 0.0092, by GLM adjusted by age and BMI). PRO as evalu-
ated by von Korff Index and PHQ-D were better in the self-
treatment-group patients. The groups did not differ in the mean
component scores of SF-36. CONCLUSIONS: Patients in self-
treatment-group in this study had the lowest societal mean total
costs per patient and better PRO’s (as evaluated by von Korff
Index and PHQ-D) compared to other groups. No major differ-
ences were detected between guideline and non-guideline
patients.
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OBJECTIVES: To assess PRO and costs in German patients with
back pain, speciﬁcally for guideline, non-guideline, and self-
treatment-groups. METHODS: Patients (n = 145) were recruited
by physicians in general practice (n = 54) in 2005. Resource
utilization data due to back pain was collected retrospectively
for six months. Patients completed the generic SF-36, and
the disease-speciﬁc Hannover Functional Questionnaire (FFbH),
von Korff Index and Patient Health Questionnaire Depression
(PHQ-D) forms at the time of enrollment. Groups were com-
pared using multivariable general linear modeling (GLM).
RESULTS: Patients (n = 72 self-treatment, n = 29 guideline-,
n = 44 non-guideline-groups) were on average 54 years old,
64% of them were women. Patients with self-treatment were
younger, more likely to be employed and had lower BMI than
patients in guideline or non-guideline-group (mean age 49.8 vs.
59.4 vs. 57.4 years; mean BMI 24.9 vs. 28.2 vs. 26.8). Average
duration of back pain was about 7.3 years and was comparable
among the groups. The groups differed regarding the SF-36, the
von Korff index, FFbH-R and frequency of PHQ-D somatoform
symptoms. The self-treatment group reported the highest mean
physical component of the SF-36 compared to other groups
(39.6  10.4, p = 0.0011, adjusted by age). Mean total societal
perspective costs per patient were (€417.61 [95%CI 171.03;
664.18] vs. €3159.17 [95%CI 933.62; 5384.73] vs. €1640.58
[95%CI 818.02; 2463.13], self-treatment-vs. guideline vs. non-
guideline-group, respectively). The major cost factors were: in
the self-treatment-group, reduction of earning capacity (43.4%),
sport activities (26.9%), and remedies (19.3%); in the guideline-
group, sick leaves (64.0%), prescribed medications (10.1%), and
visits to physicians (6.2%); and in the non-guideline-group,
sick leaves (23.8%), remedies (20.7%), and reduction of earn-
ing capacity (12.7%). CONCLUSIONS: PRO seem to be better
and costs lower in self-treatment-group. The major cost
factors are different among guideline, non-guideline and self-
treatment-groups, while costs are positively related to age and
unemployment.
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OBJECTIVES: Renal impairment after transplant is associated
to a greater risk of death. It is of interest to asses how and when
the diagnosis is made. To evaluate the diagnostic method of renal
dysfunction (Clinical or Histological). METHODS: Observa-
tional and multicenter study including 872 renal transplant
patients with at least two years post-transplant. Data were ret-
rospectively collected at ﬁve time pointssince transplant. Clini-
Abstracts A649
cians were asked if they considered that the patient had CGD
and also objective criteria (serum creatinine  2 mg/dl or
MDRD  50 ml/min), were applied. RESULTS: A total of 872
patients were analyzed 62% male, mean (SD) age 54 (13) years.
Ethiology of end stage renal failure: 32.7% chronic glomerulo-
nephritis, 19.8% unknown, 12.4% polycystic disease, 7.6%
chronic pielonephritis, 8% diabetes, 5.9% hypertension, 15.7%
other. Mean (SD) transplant evolution 8.2 (5.1) years. Mean
donor age 42 years. CGD was diagnosed in 35% of the patients
according to the investigators’ criteria and in 55.5% according to
objective criteria. In 40% of the patients that were diagnosed of
CGD by objective criteria the clinician had not considered this
diagnosis. Graft biopsy was performed in 31% of patients with
investigators’ criteria of CGD. The presence of proteinuria con-
ducted to a biopsy more than a rise in serum creatinine. Time
from transplant to biopsy was greater in patients with antipro-
teinuric treatment (p = 0,032). Immunosuppressive treatment
changes were not associated to biopsy histological data. The
creatinine slope showed a direct relationship with the total
number of treated acute rejections (Pearson’s r: 0,12; p < 0.001).
CONCLUSIONS: This study shows an existing difference
between the clinician’s perception of CGD and its objective pres-
ence. Nephrologists are more sensitive to glomerular disease than
to renal impairment itself. Changes in the immunosuppressive
treatment due to presence of CGD are performed late and with
poor results.
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OBJECTIVES: The number of prevalent patients with end-stage
renal disease (ESRD) in Greece has grown nearly 13% since
2003. Approximately 83% of prevalent ESRD patients are on
dialysis, the rest have a functioning kidney transplant. For
ESRD patients needing dialysis, two treatment options are
available, hemodialysis (HD) and peritoneal dialysis (PD). Both
have been shown to have similar outcomes yet most (91%)
dialysis patients in Greece receive HD. The objective of this
evaluation is to project a ﬁve-year impact on total direct dialy-
sis costs if utilization of the less expensive equally, effective PD
were increased to 15% of all dialysis. METHODS: An Excel-
based budget impact model was used to estimate the impact of
a shift in modality utilization. The model takes into account
dialysis modality shares, annual average cost of treating
patients per modality, annual ESRD growth rate, patient years
at risk and years to reach new dialysis modality distribution.
Cost data from a recent Greek study were used. At baseline
(2007) there were 8189 patients undergoing dialysis therapy,
91% using HD and 9% using PD. Annual direct cost per
patient were €36,247 for in-center HD and €30,719 for PD. We
applied a 2% annual ESRD growth rate; set the target PD
modality share at 15%, and that this target would be achieved
in the ﬁfth year. Total costs included equipment/infrastructure,
diagnostic services, drugs and consumables, staff salaries, and
operational costs/overheads. RESULTS: If PD utilization gradu-
ally increases to 15% by 2012, the cumulative 5-year cost
would be reduced by €6.5 million. Alternatively, the savings
could provide an additional 258 patient-years of dialysis treat-
ment. CONCLUSIONS: In Greece, an increased use of PD can
reduce the direct costs of dialysis treatment which then
provides an opportunity to use scarce health care resources on
other pressing needs.
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OBJECTIVES: The number of prevalent patients with end-stage
renal disease (ESRD) in Turkey has grown nearly 36% from
2001 to 2005. Approximately 90% of prevalent ESRD patients
are on dialysis, the rest have a functioning kidney transplant. For
ESRD patients needing dialysis, two treatment options are avail-
able, hemodialysis (HD) and peritoneal dialysis (PD). Both have
been shown to have similar outcomes yet most (87%) dialysis
patients in Turkey receive HD. The objective of this evaluation
is to project a ﬁve-year impact on total direct dialysis costs if
utilization of the less expensive equally effective PD were
increased to 20% of all dialysis. METHODS: An Excel-based
budget impact model was used to estimate the impact of a shift
in modality utilization. The model takes into account dialysis
modality shares, annual average cost of treating patients per
modality, annual ESRD growth rate, patient years at risk and
years to reach new dialysis modality distribution. Cost data from
a recent Turkish study were used. At baseline (2005) there were
39,161 patients undergoing dialysis therapy, 13% using PD.
Annual costs per patient were US$23,342 for in-center HD and
US$17,779 for PD. We applied a 6% annual ESRD growth rate;
set the target PD modality share at 20%, and that this target
would be achieved in the ﬁfth year. Total costs included the costs
of dialysis related supplies (e.g., dialysis solutions) and the cost of
drugs (e.g., erythropoietin). RESULTS: If PD utilization gradu-
ally increases to 20% by 2010, the cumulative 5-year cost would
be reduced by $38.8 million. Alternatively, the savings could
provide an additional 2420 patient-years of dialysis treatment.
CONCLUSIONS: In Turkey, an increased use of PD can reduce
the dialysis and drug-related costs of dialysis treatment which
then provides an opportunity to use scarce health care resources
on other pressing needs.
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OBJECTIVES: To investigate the pharmacoeconomic perfor-
mance of the treatment with solifenacin, a bladder-selective
muscarinic receptor antagonist, as compared to tolterodine and
placebo, in Italian patients with overactive bladder (OAB).
METHODS: A simple Markov model simulates 52-weeks clini-
cal and economical outcomes associated with the treatment with
solifenacin (5 mg/die), tolterodine ER (4 mg/die), and no treat-
ment, in a cohort representative of the Italian OAB population,
relying on RCT efﬁcacy and national cost data, and using 1-week
cycles. Only direct health care costs were considered. The main
analysis is conducted from the point of view of the patient, as
drugs for OAB are not currently reimbursed in Italy, whereas
incontinence medical devices are only to few selected patients. A
complementary scenario was elaborated to explore the conse-
quences of a hypothetical reimbursement decision by the Italian
NHS at half of the current retail price and only to incontinent
and responding OAB patients. RESULTS: Both active treatments
produce signiﬁcant improvements in symptoms and quality of
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